Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right ventricular dysfunction and exercise limitation and progresses to death. New findings from translational studies have suggested alternative pathways for treatment. These avenues include sex hormones, genetic abnormalities and DNA damage, elastase inhibition, metabolic dysfunction, cellular therapies, and anti-inflammatory approaches. Both novel and repurposed compounds with rationale from preclinical experimental models and human cells are now in clinical trials in patients with PAH. Findings from these studies will elucidate the pathobiology of PAH and may result in clinically important improvements in outcome.

中文翻译：

---

肺动脉高压的新兴疗法。

肺动脉高压（PAH）是一种肺血管病变，可导致右心室功能障碍和运动受限并进展至死亡。转化研究的新发现提出了替代治疗途径。这些途径包括性激素、遗传异常和 DNA 损伤、弹性蛋白酶抑制、代谢功能障碍、细胞疗法和抗炎方法。具有临床前实验模型和人体细胞原理的新型化合物和重新利用的化合物目前正在 PAH 患者中进行临床试验。这些研究的结果将阐明 PAH 的病理学，并可能导致临床结果的重要改善。